Amgen (MEX:AMG N) Total Liabilities : MXN1,641,305 Mil (As of Sep. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Amgen Total Liabilities?

Amgen's Total Liabilities for the quarter that ended in Sep. 2024 was MXN1,641,305 Mil.

Amgen's quarterly Total Liabilities increased from Mar. 2024 (MXN1,459,773.40 Mil) to Jun. 2024 (MXN1,556,879.00 Mil) and increased from Jun. 2024 (MXN1,556,879.00 Mil) to Sep. 2024 (MXN1,641,304.65 Mil).

Amgen's annual Total Liabilities increased from Dec. 2021 (MXN1,117,295.01 Mil) to Dec. 2022 (MXN1,198,224.16 Mil) and increased from Dec. 2022 (MXN1,198,224.16 Mil) to Dec. 2023 (MXN1,543,332.58 Mil).

Amgen Total Liabilities Historical Data

The historical data trend for Amgen's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Total Liabilities Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

943,641.24

1,064,997.79

1,117,295.01

1,198,224.16

1,543,332.58

Amgen Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															1,443,643.35	1,543,332.58	1,459,773.40	1,556,879.00	1,641,304.65

Amgen Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Amgen's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	312190.369	+	(1072263.246	+	118921.581
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	39957.38	+	0)
	=	1,543,333

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1649116.089	-	105783.513
	=	1,543,333

Amgen's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	399949.374	+	(1119472.317	+	88192.854
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	33690.103	+	0)
	=	1,641,305

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	1789513.536	-	148208.888
	=	1,641,305

Amgen Total Liabilities Related Terms

Thank you for viewing the detailed overview of Amgen's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (MEX:AMG N) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AMGN:USA 1AMGN:Italy AMGd:UK AMG:Germany AMG:Germany AMG:Germany AMG:Germany AMGN:Chile AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen Headlines

No Headlines